Tyra Biosciences Inc 2026年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF For the quarterly period ended March 31, 2026 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934For the transition period from _________ to _________.Commission File Number: 001-40800 TYRA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒As of May 8, 2026, the registrant had 59,470,381 shares of common stock, $0.0001 par value per share, outstanding. Table of Contents PART I.FINANCIAL INFORMATION Item 1.Condensed Financial Statements Condensed Statements of Cash FlowsNotes to the Condensed Financial StatementsItem 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations 15Item 3.Quantitative and Qualitative Disclosures About Market Risk23Item 4.Controls and Procedures23 OTHER INFORMATIONLegal ProceedingsRisk FactorsUnregistered Sales of Equity Securities and Use of ProceedsDefaults Upon Senior SecuritiesMine Safety DisclosuresOther InformationExhibits PART II. PART I—FINANCIAL INFORMATION Tyra Biosciences, Inc.Condensed Balance Sheets(in thousands, except share and per share data) Tyra Biosciences, Inc.Condensed Statements of Operations and Comprehensive Loss Tyra Biosciences, Inc.Condensed Statements of Stockholders’ Equity Tyra Biosciences, Inc.Notes to the Condensed Financial Statements 1. Organization and Summary of Significant Accounting Policies Organization Tyra Biosciences, Inc. (the Company) was incorporated in the state of Delaware on August 2, 2018. The Company is aclinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities inFibroblast Growth Factor Receptor (FGFR) biology. The Company’s in-house precision medicine platform, SNÅP, enables rapidand precise drug design through iterative molecular SNÅPshots that help predict which product candidates may demonstrate the Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with generally acceptedaccounting principles in the United States (GAAP) for interim financial information and pursuant to the instructions of theSecurities and Exchange Commission (SEC) on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include allof the information and disclosures required by GAAP for complete financial statements. Any reference in these notes to applicableguidance is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates(ASU) promulgated by the Financial Accounting Standards Board (FASB). The unaudited condensed financial statements includeonly normal and recurring adjustments that the Company believes are necessary to fairly state the Company’s financial position and Summary of Significant Accounting Policies During the three months ended March 31, 2026, there have been no changes to the Company’s significant accountingpolicies as described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. Fair Value Measurements The Company measures cash equivalents and available-for-sale debt securities at fair value. Fair value is defined as an exitprice, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction betweenmarket participants. Therefore, fair value is a market-based measurement that is determined based on assumptions that marketparticipants would use in pricing an asset or liability. Fair value is affected by a number of factors, including the type of asset or Level 1—Unadjusted quoted prices in active markets that are accessible at the measurement date for